Streetbeat News

Stock Prices

CCSI

Consensus Cloud Solutions shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY24 and Q3 EPS guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:10 pm

RCAT

Red Cat Holdings (NASDAQ:RCAT) reported Q4 2024 GAAP EPS of $(0.09), missing the $(0.05) estimate by 80%. Sales were $6.309M, missing the $6.643M estimate by 5.02%, but up 186.12% from $2.205M last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:09 pm

PBI

Pitney Bowes (NYSE:PBI) reported Q2 2024 adjusted EPS of $0.03, significantly beating the analyst estimate of $(0.07). The company also reported sales of $793.170 million, surpassing the $771.648 million estimate and showing a 2.15% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:09 pm

VERI

Veritone (NASDAQ:VERI) reported Q2 EPS of $(0.18), missing the $(0.15) estimate, and sales of $30.99M, slightly below the $31.00M estimate. Despite the misses, EPS improved by 48.57% and sales increased by 10.82% year-over-year.

Portfolio Pulse from totan@benzinga.com

August 08, 2024 | 9:09 pm

RRBI

Red River Bancshares has entered into a private stock repurchase agreement with two shareholders to buy back 60,000 shares for $3 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:08 pm

CLDX

Celldex Therapeutics (NASDAQ:CLDX) reported better-than-expected Q2 results with an EPS of $(0.54) beating the $(0.60) estimate and sales of $2.50M surpassing the $820.43K estimate. This marks significant improvements over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:08 pm

HNST

Honest Company shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:07 pm

INOD

Innodata Inc. has announced that it may offer up to $50 million in common stock, preferred stock, debt securities, warrants, and units from time to time.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:07 pm

VTYX

Ventyx Biosciences (NASDAQ:VTYX) reported a Q2 EPS of $(0.45), beating the analyst consensus estimate of $(0.57) by 21.05%. This represents a 50.55% improvement over the $(0.91) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:06 pm

EXFY

Expensify (NASDAQ:EXFY) reported Q2 2024 adjusted EPS of $0.06, beating the analyst estimate of $0.04. However, sales of $33.288 million missed the $36.148 million estimate and were down 14.39% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:06 pm